PharmaShots | Incisive News in 3 Shots

Subscribe Now

Fda approval

AstraZeneca and the US NIAID Report Results of Fasenra (benralizumab) in P-II Study for Hypereosinophilic Syndromes (HES)

AstraZeneca and the US NIAID Report Results of Fasenra (benralizumab) in P-II Study for Hypereosinophilic Syndromes (HES)

April 4, 2019

Clarus Therapeutics' Jatenzo (Testosterone Undecanoate Capsules for Oral Use) (CIII) Receives FDA'S Approval for Testosterone Replacement Therapy in Certain Adult Men

Clarus Therapeutics' Jatenzo (Testosterone Undecanoate Capsules for Oral Use) (CIII) Receives FDA'S Approval for Testosterone Repl...

March 27, 2019

Roche's Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) Receives FDA's Approval for Patients with HER2-Positive Breast Cancers

Roche's Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) Receives FDA's Approval for Patients with HER2-Positive Breast Canc...

March 1, 2019

Teva's ProAir Digihaler (Albuterol Sulfate 117 mcg) Inhalation Powder Receives FDA Approval for Asthma & COPD Patients Aged 4 Years or Older

Teva's ProAir Digihaler (Albuterol Sulfate 117 mcg) Inhalation Powder Receives FDA Approval for Asthma & COPD Patients Aged 4...

December 31, 2018

Merck's Keytruda (pembrolizumab) Receives FDA Approval for the Treatment of Hepatocellular Carcinoma (HCC)

Merck's Keytruda (pembrolizumab) Receives FDA Approval for the Treatment of Hepatocellular Carcinoma (HCC)

November 12, 2018

AstraZeneca's Lumoxiti Receives FDA approval for the Treatment of R/R 2L+ Hairy Cell Leukemia in patients

AstraZeneca's Lumoxiti Receives FDA approval for the Treatment of R/R 2L+ Hairy Cell Leukemia in patients

September 14, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us